ES2679618T3 - Compuestos de 3,4-diamino-6-cloropirazina-2-carboxamida para el tratamiento de enfermedades mediadas por ENAC - Google Patents

Compuestos de 3,4-diamino-6-cloropirazina-2-carboxamida para el tratamiento de enfermedades mediadas por ENAC Download PDF

Info

Publication number
ES2679618T3
ES2679618T3 ES15713339.8T ES15713339T ES2679618T3 ES 2679618 T3 ES2679618 T3 ES 2679618T3 ES 15713339 T ES15713339 T ES 15713339T ES 2679618 T3 ES2679618 T3 ES 2679618T3
Authority
ES
Spain
Prior art keywords
amino
diamino
methylbenzyl
propyl
hexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15713339.8T
Other languages
English (en)
Spanish (es)
Inventor
Susanne Elisabeth BERGLUND
Stephen Connolly
Martin Hemmerling
Nafizal Hossain
Anna Kristoffersson
Johan Rune Michael Lundkvist
Grigorios Nikitidis
Lena Elisabeth RIPA
Igor Shamovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2679618T3 publication Critical patent/ES2679618T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES15713339.8T 2014-03-18 2015-03-17 Compuestos de 3,4-diamino-6-cloropirazina-2-carboxamida para el tratamiento de enfermedades mediadas por ENAC Active ES2679618T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461954674P 2014-03-18 2014-03-18
US201461954674P 2014-03-18
PCT/GB2015/050765 WO2015140527A1 (en) 2014-03-18 2015-03-17 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2679618T3 true ES2679618T3 (es) 2018-08-29

Family

ID=52780553

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15713339.8T Active ES2679618T3 (es) 2014-03-18 2015-03-17 Compuestos de 3,4-diamino-6-cloropirazina-2-carboxamida para el tratamiento de enfermedades mediadas por ENAC

Country Status (38)

Country Link
US (3) US9873678B2 (ja)
EP (1) EP3119752B1 (ja)
JP (1) JP6502469B2 (ja)
KR (1) KR102296041B1 (ja)
CN (1) CN106103423B (ja)
AP (1) AP2016009447A0 (ja)
AR (1) AR099790A1 (ja)
AU (1) AU2015233195B2 (ja)
CA (1) CA2941807C (ja)
CL (1) CL2016002303A1 (ja)
CR (1) CR20160479A (ja)
CY (1) CY1120509T1 (ja)
DK (1) DK3119752T3 (ja)
DO (1) DOP2016000232A (ja)
EA (1) EA029952B1 (ja)
ES (1) ES2679618T3 (ja)
GT (1) GT201600190A (ja)
HR (1) HRP20181123T1 (ja)
HU (1) HUE039425T2 (ja)
IL (1) IL247610B (ja)
LT (1) LT3119752T (ja)
ME (1) ME03056B (ja)
MX (1) MX368577B (ja)
NI (1) NI201600134A (ja)
NZ (1) NZ724063A (ja)
PE (1) PE20170205A1 (ja)
PH (1) PH12016501808A1 (ja)
PL (1) PL3119752T3 (ja)
PT (1) PT3119752T (ja)
RS (1) RS57487B1 (ja)
SG (1) SG11201607751SA (ja)
SI (1) SI3119752T1 (ja)
SV (1) SV2016005278A (ja)
TR (1) TR201810207T4 (ja)
TW (1) TWI687410B (ja)
UY (1) UY36034A (ja)
WO (1) WO2015140527A1 (ja)
ZA (1) ZA201607136B (ja)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577418A (en) 1969-02-12 1971-05-04 Merck & Co Inc Pyrazinamide derivatives and processes for their preparation
US3573306A (en) 1969-03-05 1971-03-30 Merck & Co Inc Process for preparation of n-substituted 3,5-diamino-6-halopyrazinamides
FI820266L (fi) 1981-02-02 1982-08-03 Ici Plc Alkanolaminderivater
US4550111A (en) 1982-01-29 1985-10-29 Imperial Chemical Industries Plc Alkanolamine derivatives
GB8810933D0 (en) 1987-05-26 1988-06-15 Ici America Inc Heterocyclic compounds
GB8810934D0 (en) 1987-05-26 1988-06-15 Ici America Inc Amides
US4803206A (en) 1988-03-07 1989-02-07 Schering Corporation Antihypertensive acylpyrazines
GB8812343D0 (en) 1988-05-25 1988-06-29 Ici America Inc Amino compounds
GB8812342D0 (en) 1988-05-25 1988-06-29 Ici America Inc Bicyclic compounds
US6403587B1 (en) 1997-02-26 2002-06-11 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-α binding to its CCR 1 receptor
GB9930557D0 (en) 1999-12-23 2000-02-16 Rolic Ag Optically active materials
KR100840816B1 (ko) 2000-05-12 2008-06-23 젠자임 코포레이션 TNF-α시그널링의 조절물질
EA200400648A1 (ru) 2001-11-08 2005-04-28 Элан Фармасьютикалз, Инк. N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040087571A1 (en) 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
EP1581499A1 (en) 2002-12-20 2005-10-05 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US8202893B2 (en) 2004-10-13 2012-06-19 University Of Connecticut Cannabinergic lipid ligands
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AU2008221263B2 (en) 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
JP5244904B2 (ja) 2007-05-07 2013-07-24 ノバルティス アーゲー 有機化合物
ES2654395T3 (es) 2007-12-10 2018-02-13 Novartis Ag Análogos de amilorida espirocíclicos como bloqueantes de ENaC
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
CA2723938A1 (en) 2008-05-13 2009-11-19 Novartis Ag 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
AU2009256645A1 (en) * 2008-06-10 2009-12-17 Novartis Ag Pyrazine derivatives as epithelial sodium channel blockers
WO2011028740A1 (en) * 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013192517A2 (en) 2012-06-21 2013-12-27 Whitehead Institute For Biomedical Research Compounds for treating infectious diseases
GEP20186903B (en) 2012-12-17 2018-10-25 Saiensis Ink Perion Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds

Also Published As

Publication number Publication date
CR20160479A (es) 2017-02-24
KR102296041B1 (ko) 2021-08-30
PT3119752T (pt) 2018-07-24
PE20170205A1 (es) 2017-04-06
CA2941807A1 (en) 2015-09-24
TW201620880A (zh) 2016-06-16
US20170107195A1 (en) 2017-04-20
MX368577B (es) 2019-10-08
US20190330187A1 (en) 2019-10-31
HUE039425T2 (hu) 2018-12-28
DOP2016000232A (es) 2016-10-16
AU2015233195B2 (en) 2017-04-20
EP3119752A1 (en) 2017-01-25
CY1120509T1 (el) 2019-07-10
PH12016501808B1 (en) 2017-01-09
ZA201607136B (en) 2018-04-25
DK3119752T3 (en) 2018-07-30
AR099790A1 (es) 2016-08-17
AP2016009447A0 (en) 2016-09-30
WO2015140527A1 (en) 2015-09-24
AU2015233195A1 (en) 2016-09-22
RS57487B1 (sr) 2018-10-31
CN106103423A (zh) 2016-11-09
US9873678B2 (en) 2018-01-23
SV2016005278A (es) 2016-11-30
TR201810207T4 (tr) 2018-08-27
CL2016002303A1 (es) 2017-01-13
LT3119752T (lt) 2018-08-10
NZ724063A (en) 2018-02-23
IL247610A0 (en) 2016-11-30
CN106103423B (zh) 2019-12-06
JP6502469B2 (ja) 2019-04-17
EA029952B1 (ru) 2018-06-29
GT201600190A (es) 2019-07-29
TWI687410B (zh) 2020-03-11
EA201691641A1 (ru) 2017-02-28
EP3119752B1 (en) 2018-05-16
US10336725B2 (en) 2019-07-02
ME03056B (me) 2018-10-20
UY36034A (es) 2015-09-30
PH12016501808A1 (en) 2017-01-09
HRP20181123T1 (hr) 2018-09-21
JP2017512830A (ja) 2017-05-25
IL247610B (en) 2019-05-30
KR20160127135A (ko) 2016-11-02
US10954211B2 (en) 2021-03-23
US20180162838A1 (en) 2018-06-14
MX2016011681A (es) 2016-10-28
CA2941807C (en) 2023-03-07
SG11201607751SA (en) 2016-10-28
SI3119752T1 (en) 2018-08-31
NI201600134A (es) 2017-03-13
PL3119752T3 (pl) 2018-09-28

Similar Documents

Publication Publication Date Title
US11155532B2 (en) Cyclopropylamines as LSD1 inhibitors
US11739094B2 (en) Substituted benzodiazoliums as ENaC inhibitors
EP3794002A1 (en) Compounds
US20230159511A1 (en) Tetrahydroisoquinoline compounds as nrf2 activators
ES2679618T3 (es) Compuestos de 3,4-diamino-6-cloropirazina-2-carboxamida para el tratamiento de enfermedades mediadas por ENAC
BR112016021187B1 (pt) Compostos químicos e combinação compreendendo os mesmos
RU2512318C2 (ru) Производные изохинолина, ингибирующие р38 киназу